Form 4: Nautilus Biotechnology Executive Acquires Stock Options

Subramanian Sankar, Senior VP of Product Development at Nautilus Biotechnology, acquired stock options for 160,000 shares on March 1, 2024.

Summary

• Subramanian Sankar, Senior VP of Product Development at Nautilus Biotechnology, Inc., filed a Form 4 on March 5, 2024.
• The form reports a transaction that occurred on March 1, 2024, where Sankar acquired stock options for 160,000 shares of Nautilus Biotechnology common stock.
• The exercise price of the options is $2.72 per share.
• The options vest over time, with 25% vesting on January 1, 2025 (one year after the Vesting Commencement Date of January 1, 2024), and the remaining shares vesting monthly thereafter over 36 months, contingent upon continuous service as a 'Service Provider'.
• The options expire on March 1, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The grant of stock options can be seen as a mildly positive sign, indicating the company's desire to retain key personnel.

Positives

• The acquisition of stock options by a senior executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests a multi-year commitment from the executive.

Industry Context

This is a standard SEC filing related to executive compensation. Stock options are a common tool used to incentivize and retain key personnel in publicly traded companies, particularly in the biotechnology sector.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for executives in biotech companies like Nautilus Biotechnology.
• Companies such as Illumina, Pacific Biosciences, and Bio-Rad Laboratories also utilize stock options to align executive interests with shareholder value.
• The vesting schedule described is fairly standard, with vesting occurring over a multi-year period contingent on continued employment.

Stakeholder Impact

• The granting of stock options aligns the executive's interests with those of the shareholders, as the value of the options increases with the company's stock price.

Key Dates